Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
| Revenue (TTM) | $141.06M |
| Gross Profit (TTM) | $98.97M |
| EBITDA | $47.66M |
| Operating Margin | 39.70% |
| Return on Equity | 90.60% |
| Return on Assets | 20.40% |
| Revenue/Share (TTM) | $5.11 |
| Book Value | $3.02 |
| Price-to-Book | 28.96 |
| Price-to-Sales (TTM) | 11.44 |
| EV/Revenue | 12.8 |
| EV/EBITDA | 64.80 |
| Quarterly Earnings Growth (YoY) | -12.60% |
| Quarterly Revenue Growth (YoY) | 157.90% |
| Shares Outstanding | $28.58M |
| Float | $22.50M |
| % Insiders | 4.89% |
| % Institutions | 71.77% |
Volatility is currently expanding
ETON raises its 2026 revenue outlook as Q3 sales surge 158%, fueled by HEMANGEOL growth, improving profitability and rare disease pipeline progress.
Eton Pharmaceuticals NASDAQ: ETON reported third-quarter revenue of $57.9 million, up 158% from a year earlier, and raised its full-year outlook after a full quarter of sales from HEMANGEOL and growth across its product portfolio.
Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully diluted EPS of $0.50; EBITDA of $24.8 million, Adjusted EBITDA of $28.5 million or 49% of revenue Raised 2026 revenue guidance to more than $175 million, up from prior guidance of more than $145 million; raised 2026 Adjusted EBITDA to more than 40%, up from prior guidance of more than 35% Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2026.
DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will present at the 2026 Jefferies Global Healthcare Conference in London from November 16-19, 2026 as follows:
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved Commercial preparations remain on track to support a potential U.S. launch of Anaphylm following FDA approval Ex-U.S. Anaphylm strategy progressing, with Health Canada submission expected in Q4 2026 and an EU filing planned for Q1 2027 Company to host investor call on November 4, 2026, at 8:00 a.m. ET WARREN, N.J.
Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.
DEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced ET-900, a new development program evaluating mecasermin injection for the treatment of infantile and epileptic spasms. Mecasermin is a recombinant form of IGF-1 and the active ingredient in INCRELEX, which Eton markets in the United States. The Company has entered into a license agreement with Baylor College of Medicine covering patent rights related to the use of IGF-1 for the treatment of spasms.
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2026 financial results on Thursday, November 5, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.
DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, and Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that they have entered into an exclusive license agreement and a supply agreement covering the United States and its territories for LIBERVANT® (diazepam) buccal film, an Orphan Drug-designated, differentiated treatment for seizure clusters in patients with epilepsy. Eton anticipates commercial availability of LIBERVANT in April 2027, subject to final U.S. Food and Drug Administration (FDA) approval.
Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ETON and any ticker you trade — then tracks every position and per-strategy win rate.
